< Back to previous page
Researcher
Toon Van Gorp
- Disciplines:Cancer diagnosis, Cancer therapy, Oncological surgery, Cancer biology
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Oct 2019 → 30 Sep 2022
Projects
1 - 5 of 5
- Liquid biopsy and HRD testing in ovarian cancerFrom4 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- PPP2R1A as a new biomarker in type-II endometrial cancers.From1 Jan 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Predictive genetic markers for targeted therapy in gynaecological cancers: bridging the gap between “one-size-fits-all” and personalized treatmentFrom8 Oct 2020 → 30 Sep 2022Funding: BOF - projects
- Predictive genetic markers in gynaecological cancers: how to improve targeted therapy.From1 Oct 2020 → TodayFunding: FWO fundamental clinical research fellowship
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → 11 Oct 2023Funding: FWO Strategic Basic Research Grant
Publications
21 - 30 of 140
- The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer(2023)
Authors: Toon Van Gorp
- TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum(2023)
Authors: Toon Van Gorp
- Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study)(2023)
Authors: Toon Van Gorp
- First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62)(2023)
Authors: Toon Van Gorp
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study(2023)
Authors: Toon Van Gorp
Pages: 343 - 344 - Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study(2023)
Authors: Toon Van Gorp
Pages: 2436 - + - Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors(2023)
Authors: Toon Van Gorp
- Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?(2023)
Authors: Ignace Vergote, Toon Van Gorp
Pages: 201 - 211 - CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study(2023)
Authors: Diether Lambrechts, Liselore Loverix, Toon Van Gorp, Els Van Nieuwenhuysen, Ignace Vergote
Pages: 697 - 713 - tRNA-derived small RNA 3'U-tRFValCAC promotes tumour migration and early progression in ovarian cancer(2023)
Authors: Toon Van Gorp
Pages: 134 - 145